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In developed societies, diseases of metabolic
origin such as hyperlipidemia, diabetes, and obe-
sity have become increasingly prevalent. These
disorders have a complex etiology involving ge-
netic and nutritional factors. Intense research over
the past decade has yielded evidence that a group
of nuclear hormone receptors, called peroxisome
proliferator-activated receptors (PPARs), are at-
tractive target for pharmaceutical intervention of
these diseases [1]. More recently, these receptors
have also been shown to be involved in epidermal
wound repair during the different phases of the
healing process. Furthermore, they stimulate ker-
atinocyte migration and differentiation and pro-
tect them from cytokine-induced apoptosis, sug-
gesting that they promote keratinocyte survival
after an injury [2]. It is mainly these two aspects 
of PPAR biology, control of lipid metabolism and
energy homoeostasis and function in epidermal
differentiation and repair, which will be discussed
below.
Peroxisome proliferator-activated receptors
control many cellular and metabolic processes.
They are transcription factors belonging to the
family of ligand-inducible nuclear receptors.
Three isotypes called PPARα, PPARβ/δ and
PPARγ have been identified in lower vertebrates
and mammals. They display differential tissue dis-
tribution and each of the three isotypes fulfills spe-
cific functions. PPARα and PPARγ control energy
homoeostasis and inflammatory responses. Their
activity can be modulated by drugs such as the hy-
polipidaemic fibrates and the insulin sensitising
thiazolidinediones (pioglitazone and rosiglita-
zone). Thus, these receptors are involved in the
control of chronic diseases such as diabetes, obe-
sity, and atherosclerosis. Little is known about the
main function of PPARβ, but it has been impli-
cated in embryo implantation, tumorigenesis in
the colon, reverse cholesterol transport, and re-
cently in skin wound healing. Here, we present re-
cent developments in the PPAR field with par-
ticular emphasis on both the function of PPARs 
in lipid metabolism and energy homoeostasis
(PPARα and PPARγ), and their role in epidermal
maturation and skin wound repair (PPARα and
PPARβ).
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Summary
Introduction
Expression and molecular mode of action of PPARs
The PPARs were first cloned as nuclear re-
ceptors that mediate the effects of synthetic com-
pounds called peroxisome proliferators because
these compounds stimulate peroxisome prolifera-
tion in the liver of rodents. PPARs are transcrip-
tion factors that directly modulate gene activity
(review in [3]). Their molecular mode of action is
the same as that of many nuclear hormone recep-
tors. They can be activated by specific ligands and
then modulate DNA transcription by binding to
defined nucleotide sequences in the promoter re-
gion of target genes. Thus, in a simplified view, the
effector function of the nuclear receptors in a cell
is to adapt the gene expression program in re-
sponse to signals received in form of lipophilic lig-
ands. Nuclear receptors share a common modular
structural organisation. A poorly structured N ter-
minal domain that may comprise a ligand-inde-
pendent transactivation domain is followed by the
DNA binding domain (DBD) folded in two zinc
fingers, which is the hallmark of members of the
nuclear receptor family. A hinge region then links
the DNA binding domain to the ligand binding
domain (LBD) that comprises a ligand binding
pocket and a ligand-dependent transactivation do-
main. Nuclear receptors bind to DNA in form of
dimers, either homodimers or more often het-
erodimers with the receptor for 9-cis retinoic acid
known as retinoid X receptor (RXR), which is in-
deed the obligate partner of PPARs. The DNA re-
sponse element of nuclear receptors comprises two
short hexameric sequence motifs corresponding to
or closely related to AGGTCA. The organization
of these motifs in direct repeats or palindromes and
the length of the spacing between the two hexam-
ers determine the binding specificity of the re-
sponse elements towards each kind of family mem-
ber dimers. The peroxisome proliferator response
element, which binds the PPAR:RXR hetero-
dimer, is a direct repeat of two of these motifs 
with a spacing of one nucleotide. Transcriptional
gene regulation via nuclear receptors is believed to
occur in at least two steps. In absence of ligand, the
nuclear receptor dimer is associated with a co-re-
pressor(s), a protein that inhibits its transactivation
properties. In presence of a ligand, or after activa-
tion by an alternative pathway, such as phosphory-
lation, the co-repressor is released and co-activa-
tors are recruited, allowing further contacts to be
made with the transcription machinery, which lead
to an enhancement of transcription of the target
genes (reviewed in [3] and [4]). Whereas the asso-
ciation of the unliganded PPAR:RXR heterodimer
with a co-repressor in a physiological context re-
mains to be assessed, several co-activators binding
to this heterodimer have been identified [4].
Three PPAR isotypes are known to date, α, β
(also called δ), and γ (NR1C1, NR1C2, NR1C3,
respectively) [5]. The patterns of expression of
these three PPARs contribute to the specificity of
their functions. The levels of PPARα are highest
in brown adipose tissue and in the liver, then come
the heart, the kidney, and enterocytes. PPARβ
expression is more general in terms of tissue dis-
tribution, with varying levels in different organs.
Alternate promoter usage and splicing generate
two main PPARγ isoforms, PPARγ1 and PPARγ2.
PPARγ1 is mainly expressed in the white and
brown adipose tissues, but is also detected in the
colon, the spleen, the retina, and hematopoeitic
cells. PPARγ2 has been found mainly in the white
and brown adipose tissues [6].
The PPARα isotype is the cellular target for
fibrates such as gemfibrozil, bezafibrate, and feno-
fibrate, which are hypolipidaemic drugs widely
used for the treatment of cardiovascular diseases.
The PPARγ isotype is the target for a group of
drugs called thiazolidinediones (TZDs), such as the
marketed rosiglitazone (Avandia) and pioglita-
zone (Actos), which are used in the treatment of
type 2 diabetes. TZDs are effective glucose-low-
ering drugs that produce modest effects on lipids
in these patients. Lastly, a PPARβ selective ligand,
GW501516, causes a dramatic dose-dependent
rise in serum high density lipoprotein cholesterol
while lowering the levels of small-dense low den-
sity lipoprotein, fasting triglycerides, and fasting
insulin in insulin-resistant middle-aged obese the-
sus monkeys [7].
A search for natural ligands revealed that
PPARα is activated by a variety of long-chain fatty
acids, in particular by polyunsaturated fatty acids
such as docosahexaenoic acid, eicosapentaenoic
acid, linoleic acid, linolenic acid, and arachidonic
acid. Competition binding and other assays re-
vealed that the latter three are ligands for PPARα,
PPARβ, and PPARγ, albeit with various affinities.
Fluorescence spectroscopy, an equilibirum meth-
od that does not require separation of free from
bound ligand, established that Kds for these fatty
acids is in the nanomolar range. Only PPARα
binds to a wide range of saturated fatty acids [8].
Screening of arachidonate derivatives revealed
that some eicosanoids are PPAR ligands. First, the
prostaglandin (PG) D2 metabolite 15-deoxy-∆12,
14 PG J2 was identified as a specific PPARγ ligand,
and 8(S)-hydroxy-eicosatetraenoic acid (HETE)
and leukotriene (LT) B4 were identified as PPARα
ligands. Oxidised metabolites of linoleic acid
present in oxidised low-density lipoproteins, i.e. 
9-hydroxy-octadecadienoic acid (9-HODE) and
13-HODE, have been identified as PPARγ ligands.
A specific potent PPARβ ligand among eicosanoids
has not yet been found, although endogenously
synthesised prostacyclin (PGI2) might serve as a
ligand for PPARβ [9].
The ability of PPAR to bind such a diverse va-
riety of synthetic and natural compounds has been
puzzling. Partial explanation for this ability to bind
multiple ligands came with the description of the
crystal structure of the ligand binding domain of
PPARγ [10] and PPARβ [8], and recently of PPARα
[11]. A common structural three-dimensional fold,
which consists of an antiparallel α-helical sand-
wich of 12 helices (Helix 1 to Helix 12) organised
in three layers with a central ligand binding hy-
drophobic pocket, had been previously charac-
terised in classical hormone receptors, such as the
thyroid hormone receptor (TR), the retinoic acid
receptor (RAR), and RXR [12–14]. Upon ligand
binding, the ligand binding pocket closes accord-
ing to a so-called “mouse trap model”. The ligand
binding pocket of PPARs is much larger than that
of other nuclear receptors with a volume of ~1300
Å3, of which the ligand occupies only about 30 to
40%. This cavity is larger than in other known
LBDs (compare with the cavity in TR 
~600 Å3, most of this volume, ~530 Å3, being oc-
cupied by the triiodothyronine molecule [14]).
Overall, PPARs appear to have evolved as nuclear
receptors adapted for binding to multiple natural
ligands with relatively low affinity. However, the
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comparison of the crystal structures of the ligand
binding domain of the three PPARs revealed mo-
lecular determinants of isotype specificity which
should aid in the design of drugs for the treatment
of metabolic and cardiovascular diseases [11] (see
below).
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Functions of PPARs in lipid metabolism and energy homoeostasis
The opposite and complementary roles of
PPARα and PPARγ
As can be expected from “sensor” molecules
for a variety of fatty acids and their derivatives,
PPARs regulate most of the pathways associated
with lipid metabolism. A most fascinating recent
finding is that the two isotypes α and γ have bal-
anced regulatory actions in fatty acid oxidation 
in the liver via PPARα, and in fatty acid storage in
the adipose tissue via PPARγ (fig. 1). The role of
PPARβ remains more elusive and will be discussed
later.
In addition to the identification of ligands,
there are two main and complementary ap-
proaches to study the functions of nuclear recep-
tors: characterization of their target genes to un-
veil the regulated pathways, and generation of null
allele mutant mice that are then subjected to ade-
quate physiological challenges. These approaches
have contributed to most of the present knowledge
of PPAR functions as will be presented below.
PPARα has been mainly studied in the liver
where it is highly expressed and because peroxi-
some proliferation in rodent mainly occurs in this
organ after prolonged treatment with peroxisome
proliferators. In the liver, PPARα target genes
form a comprehensive ensemble of genes which
participates in many if not all aspects of lipid ca-
tabolism (fig. 1). It includes transport of fatty acids
in the circulation, their uptake by the hepatocytes,
intracellular binding by fatty acid binding pro-
teins, activation by the acyl-CoA synthase, as well
as catabolism by β-oxidation in the peroxisomes
and mitochondria, and ω-oxidation in the micro-
somes (review in [3]). PPARα null mice are viable
and do not exhibit an obvious phenotype when
kept under normal laboratory confinement and
diet [15]. However, these mice experience serious
difficulties during fasting, a situation that normally
results in an enhanced fatty acid mobilisation and
increased β-oxidation in the liver as fatty acids rep-
resent the major energy source. Confronted to
such a metabolic challenge, PPARα null mice are
not capable of enhanced fatty oxidation and rap-
idly suffer from hypoketonemia, hypothermia, and
hypoglycemia [16, 17]. This latter observation un-
derscores the link between fatty acid and glucose
metabolism, which is essential in general energy
homoeostasis that is dependent on precise meta-
bolic adjustments.
In contrast, PPARγ is clearly involved in the
adipocyte differentiation program and lipid stor-
age [18] (fig. 1). It is a late marker of adipocyte dif-
ferentiation and its forced ectopic expression suf-
fices to push fibroblasts into the adipogenic pro-
gram. Direct target genes of PPARγ include those
coding for the adipocyte fatty acid binding protein
(aP2), lipoprotein lipase, acyl-CoA synthase, and
fatty acid transport protein. PPARγ null mice are
not viable, due to placental defects ([19], our own
unpublished results). However, a thorough analy-
sis of PPARγ heterozygous mice revealed that they
are less prone to develop insulin resistance when
chronically under high fat diet [20]. Again the link
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Figure 1
Examples of PPARα and PPARγ functions in
energy homoeostasis. PPARα and PPARγ are
regulators of opposite but complementary
functions. They are involved in the control of
genes regulating the transport of fatty acids in
the circulation, their uptake by cells (hepato-
cytes, adipocytes), intracellular binding by fatty
acid binding proteins, activation by the 
acyl-CoA synthase, as well as catabolism 
by β−oxidation in the peroxisomes and mito-
chondria and ω-oxidation in the microsomes
(PPARα, hepatocytes) or storage as triglyc-
erides (PPARγ, adipocytes). PPARs are recep-
tors for natural compounds (fatty acids and
their derivative) or synthetic coumpounds
(hypolipidaemic fibrates for PPARα and insulin
sensitising TZDs for PPARγ).
between glucose and lipid metabolism is obvious,
but further investigation is necessary to unveil the
underlying molecular mechanisms.
Not surprisingly, PPARγ agonists such as
TZDs, which are insulin sensitisers (see above),
also induce both adipocyte differentiation in cell
culture models and weight gain in rodents and
humans. We recently identified a new synthetic
PPARγ antagonist, dimethyl α-(dimethoxyphos-
phinyl)-p-chlorobenzyl phosphate (SR-202),
which inhibits both TZD-stimulated recruitment
of a transcriptional coactivator and TZD-induced
transcriptional activity of PPARγ. Functional stud-
ies using cultured cells showed that SR-202 can
indeed antagonise TZD or hormone-induced
adipocyte differentiation. In vivo, a decrease of
PPARγ activity obtained either by treatment with
SR-202 or by invalidation of one allele of the
PPARγ gene, leads to a reduction of both high-fat
diet-induced adipocyte hypertrophy and insulin
resistance. The smaller size of adipocytes in mice
with lower PPARγ activity was associated with a
decrease of both TNFα and leptin secretion and
lower plasma free fatty acid levels, which can con-
tribute to enhanced insulin sensitivity. Thus, SR-
202 is a new selective PPARγ antagonist, which is
effective both in vitro and in vivo. Because it yields
both anti-obesity and anti-diabetic effects, SR-202
may be a lead for new compounds to be used in the
treatment of obesity and type 2 diabetes [21].
The peroxisome proliferator activated
receptor α regulates amino acid metabolism
Our recent work suggests that PPARα does
not function exclusively as a regulator of lipid me-
tabolism. It also influences the expression of nu-
merous genes implicated in major pathways of
amino acid metabolism, indicating that it is a key
controller of intermediary metabolism [22]. This
control includes the transcriptional regulation of
genes involved in transamination, deamination,
urea cycle (all five enzymes), oxidation of alpha
keto acids, amino acid inter-conversions, and syn-
thesis of amino acid derived products. With the ex-
ception of hydroxypyruvate/glyoxylate reductase
and arginase, PPARα suppresses the expression of
all these genes, leading to an overall decrease in
amino acid degradation.
Contrary to common understanding, oxida-
tion of amino acids contributes to a large extent to
energy production in several organs, including
liver and gut [23]. In addition, amino acid oxi-
dation is dramatically elevated during conditions
such as sepsis and cachexia, and after severe trauma
and burns. These catabolic diseases are character-
ized by massive net body protein breakdown, lead-
ing to a negative nitrogen balance. Despite the
clinical importance of amino acid metabolism, and
unlike lipid and glucose metabolism, little infor-
mation is available about its regulation at the ge-
netic level. It has been demonstrated that gluco-
corticoids and glucagon increase expression of
urea cycle enzymes [24–26]. Furthermore, recent
work has established the important role of the
transcription factor C/EBPα in stimulating the ex-
pression of urea cycle enzymes [27]. Our data point
towards another global transcriptional regulator,
PPARα, which inhibits amino acid degradation
and has an effect directly opposite to that of
C/EBPα. In agreement with these data, plasma
urea levels are increased in fasted PPARα null mice
compared to wild-type mice.
As fatty acids are ligands for PPARα, the sup-
pressive effect of PPARα on urea cycle enzymes
may provide a potential explanation for the in-
hibitory effect of fatty acids on ureagenesis [28]
and ammonia detoxification [29]. Fatty acids have
also been shown to suppress arginino succinate
synthase and carbamoyl phosphate synthase ex-
pression in cell culture [30]. This mechanism may
account for the abnormal expression of urea cycle
enzymes observed in carnitine-deficient juvenile
visceral steatosis, a disease characterized by defec-
tive fatty acid uptake into mitochondria and asso-
ciated accumulation of fatty acids in the cytosol
[31].
Why would the same transcription factor that
stimulates hepatic fatty acid oxidation suppress
amino acid degradation and ureagenesis? Dur-
ing prolonged fasting fatty acid oxidation becomes
the major source of energy for the liver, an effect
mediated by PPARα [16, 17]. At the same time, the
relative contribution of amino acid metabolism to
hepatic ATP production, which is dominant in the
fed state, declines [23]. In mice, this is associated
with a decreased expression of several amino acid
metabolising and urea synthesising enzymes dur-
ing fasting. The reciprocal relationship between
fatty acid oxidation and nitrogen metabolism is
illustrated by comparing the plasma ketone body
concentration, which reflects the rate of fatty acid
oxidation, and the plasma urea concentration,
which in the absence of changes in renal clearance
is indicative of the rate of amino acid metabolism
and subsequent urea synthesis. It is conceivable
that the simultaneous increase in ketone body con-
centration and decrease in urea concentration dur-
ing fasting in mice are actually due to the action of
a single factor, PPARα, which balances the activi-
ties of the two pathways by altering the expression
of genes involved.
Finally, in addition to amino and fatty acid me-
tabolism, recent evidence also implicates PPARα
in the regulation of carbohydrate metabolism. It
was shown that PPARα up-regulates the expres-
sion of several genes involved in gluconeogenesis.
Overall, this suggests that PPARα acts as a global
regulator of energy metabolism in the liver, which
coordinates the rates of utilization of the various
energy substrates in relation to food availability.
This short overview of PPARα and PPARγ
functions emphasizes the regulatory network that
these two receptors govern in the organism be-
tween the liver and the adipose tissue, and between
fatty acid and glucose metabolism, allowing for a
proper adaptive response to the everyday alter-
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nance of fasting and feeding periods [1]. The main
characteristic of PPARs resides in their ability to
function as sensors of the metabolic needs of the
organism. Any perturbation in the pathways they
control is likely to provoke metabolic alterations
such as those seen in diabetes type 2, obesity, and
dyslipidaemia; thus, the strong interest of the
pharmaceutical industry in developing specific
PPAR ligands that could be used as drugs aimed at
these disorders. In addition, other pathways, no-
ticeably those underlying inflammatory reactions,
are also major research targets with respect to
PPAR functions due to the fact that the lipid me-
diators involved are PPAR ligands.
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Functions of PPARs in epidermal maturation and repair
As the outermost layer of the skin, the epider-
mis affords protection against mechanical and
chemical aggressions. It is a multistratified epithe-
lium. Progenitor undifferentiated keratinocytes
which migrate from the basal to the uppermost
layer undergo a vectorial differentiation. This pro-
gram includes a biochemical differentiation, the
sequential expression of various structural proteins
(e.g. keratins, involucrin and loricrin), and the pro-
cessing and reorganization of lipids (e.g. sterols,
free fatty acids, and sphingolipids), which will pro-
vide a hydrophobic barrier to the body. We hy-
pothesized that PPARs have specific roles in these
complex processes. 
The epidermal maturation process
The epidermis matures during the latest stages
of vertebrate foetal development and becomes
fully developed before term. Skin development is
regulated by several nuclear hormone receptors
and their respective ligands. For instance, oestro-
gen, thyroid hormones, and glucocorticoids accel-
erate the skin barrier maturation, whereas testos-
terone delays the process [32–34]. Furthermore,
retinoids are also known to influence keratinocyte
differentiation. Consistent with this observation,
the specific elimination of RXRα expression in the
murine epidermis by conditional knock out of the
gene has severe consequences on the hair follicle
cycle and the epidermal maturation [35, 36].
PPAR gene expression during epidermal
differentiation
Like the nuclear receptors mentioned above,
PPARα, β and γ are also present in rodent ker-
atinocytes [2, 6, 37–39]. Each of the three isotypes
has a specific pattern of expression, suggesting non
redundant functions during development and in
the various layers of the epidermis. PPARα, β and
γ transcripts are already present in the mouse epi-
dermis at foetal day 13.5 [39]. Their expression in
the interfollicular epidermis during mouse foetal
development parallels all the major events of the
maturation of the epidermal barrier such as, for ex-
ample, the expression of differentiation markers
(involucrin, loricrin, filaggrin) and changes in lipid
metabolism (apparition of the lipid granules).
Whether some of these events are regulated
through PPARs remains to be demonstrated.
PPAR expression decreases after birth to become
undetectable in the interfollicular epidermis of the
adult mice. In contrast, all three isotypes remain
expressed in the hair follicles. Interestingly, ex-
pression of PPARα and PPARβ can be reactivated
in the adult epidermis by stimuli inducing ker-
atinocyte proliferation (topical application of
TPA, hair plucking) [39]. The three PPAR isotypes
have been observed in human keratinocytes as well
[40–42], and PPARβ seems to be the prevalent iso-
type. Its expression remains high during the dif-
ferentiation of human keratinocytes. PPARα and γ
are expressed at lower levels, which seem to in-
crease during differentiation.
PPAR ligands and keratinocyte 
differentiation in cell culture models
The expression of the three PPAR isotypes in
the epidermis during rodent foetal development
has prompted studies on the effects of PPAR lig-
ands on keratinocyte differentiation. In the rat,
PPARα ligands accelerate rat epidermal matura-
tion in in vitro cultured keratinocytes [43–45] and
in utero [38], whereas PPARβ and γ activators had
no effects. In addition, PPARα ligands induce epi-
dermal differentiation and restore epidermal ho-
moeostasis in hyperproliferative mouse epidermis.
In human keratinocyte cell lines however, PPARα
activators seem to have no effect on cell differen-
tiation [42], but are able to influence lipid metab-
olism in an in vitro human skin model [40]. In con-
trast, a selective PPARβ ligand was reported to in-
duce the expression of differentiation markers in a
human keratinocyte cell line, whereas the PPARγ
ligand rosiglitazone had a negligible effect. Inter-
estingly, PPARβ and γ ligands, when added simul-
taneously, have a synergistic effect on human ker-
atinocyte cell line differentiation. Finally, we re-
cently demonstrated that in mouse keratinocyte
primary cultures a PPARβ ligand induces an ac-
celeration of the differentiation of the cultured
cells (see below). Overall, the effects of the PPAR
ligands on keratinocyte differentiation appear to
be quite different across species for reasons which
remain to be elucidated. However, the PPAR iso-
types exhibit important species specificity in ligand
binding, which in addition to differences in the ex-
perimental models used could account, at least in
part, for these apparent discrepancies.
PPAR functions in epidermal differentiation
in vivo
Important information on the role of PPARs
in epidermis homoeostasis has been obtained from
PPAR mutant mouse models. To address the hy-
pothesis of the involvement of PPAR in the differ-
entiation of the epidermis during mouse foetal de-
velopment, skin maturation was studied in PPAR
mutant embryos during late foetal development, at
the time of the formation of a competent epider-
mal barrier. PPARα null or PPARβ heterozygous
mutant embryonic skin showed a normal architec-
ture upon histological staining at all the embryonic
stages examined. All the characteristic layers, with
no major defect in their thickness and organiza-
tion, were present in the epidermis of these PPARα
and β mutant embryos. Similarly, the expression of
epidermal differentiation markers in the PPARα
and β deficient epidermis remained unchanged.
Together, these results suggest that the mouse
foetal epidermis is able to undergo normal matu-
ration in the absence of PPARα, and in conditions
where PPARβ expression is decreased by half. Sim-
ilarly, the epidermis of PPARγ heterozygous ani-
mals, or of the PPARγ null mice born after pla-
cental rescue, did not exhibit any obvious matura-
tion defect either [19, 39]. Moreover, PPARγ null
mutant cells were able to participate in the devel-
opment of the epidermis in mouse chimeras com-
prising PPARγ null and wild type cells, suggesting
no or little contribution of PPARγ in epidermal tis-
sue differentiation [46].
In accordance with earlier characterization of
the PPARα null mice [15, 47], we did not detect
any major defect in skin sections of PPARα null
adult animals. In contrast, comparison of PPARβ
heterozygous mice with wild type control animals
revealed a significant increase in the keratinocyte
proliferation rate in the epidermis of PPARβ adult
mutant mice [39]. This difference was even more
striking after topical application of TPA on the epi-
dermis of these animals. The well characterized
hyperplastic response observed after TPA treat-
ment of the epidermis was indeed much more pro-
nounced in the PPARβ mutant animals, strongly
suggesting a defect in the control of keratinocyte
proliferation in these heterozygous animals. Sim-
ilarly, an impaired control of keratinocyte prolif-
eration was also observed in a PPARβ null mouse
model [48]. These in vivo data demonstrate that the
PPARβ isotype has a role in the control of ker-
atinocyte proliferation in the whole animal.
These observations prompted us to test
whether PPARs are involved in adult skin wound
repair. In a skin injury the mature epithelium is dis-
rupted, and the covering of the wound by a new
epithelium starts within hours after the event. A
fully differentiated epithelium, and thus a compe-
tent protective epidermis, will eventually be re-
constituted at the wounded place. This re-epithe-
lialisation involves initially the migration of ker-
atinocytes, their proliferation, stratification, and
differentiation/maturation [49]. Using in situ hy-
bridisation, we demonstrated that PPARα and β,
but not PPARγ expression is upregulated in the
keratinocytes at the wound edges of the damaged
skin. PPARα is re-expressed transiently in this area
during the early inflammatory phase of the heal-
ing, whereas PPARβ remains expressed until com-
pletion of the process [39]. Consistent with this
pattern of PPAR expression during wound healing,
and using PPARα, β and γ mutant mice models,
PPARα and β, but not PPARγ, are necessary for
the normal healing of an excisional skin wound. 
In PPARα null mice there is a transient retar-
dation of the healing process during the inflam-
matory phase. In the PPARβ mutant mice, com-
pletion of healing is postponed for 2 to 3 days com-
pared to the wild type animals. Interestingly, in
both models, the delay observed in skin repair is
consistent with the pattern of expression of the re-
spective PPAR isotype as analysed during skin in-
jury repair [39]. Thus, there are important but non
redundant roles for PPARα and β during the re-
generation of the skin in the adult mouse. Impor-
tantly, our finding revealed that a PPARα or β mu-
tation has no obvious effect during normal foetal
development of the epidermis, but affects epider-
mal regeneration after an injury at the adult stage.
Mechanisms of PPAR action during 
wound repair
Wound repair requires the integration of in-
terdependent processes and signals that involve,
among others, soluble mediators, inflammatory
cytokines produced by a variety of cell types, cell
proliferation and migration, cell differentiation,
and production of extracellular matrix compo-
nents. As mentioned above, it comprises three suc-
cessive main phases, i.e. inflammation, re-epithe-
lisation, and tissue remodelling. During the initial
phase, keratinocytes are exposed to many pro-in-
flammatory cytokines and bioactive lipids. The hy-
pothesis that PPARα participates in the control of
the inflammatory response is reinforced by the fol-
lowing observations: a) in agreement with the in
vivo study, there is a transient increase in PPARα
expression in cultured primary keratinocytes fol-
lowing exposure to inflammatory signals, b) in-
flammatory eicosanoids, e.g. LTB4 and 8S-HETE,
which are produced after an injury are PPARα lig-
ands [50], and c) there is an alteration in the re-
cruitment of inflammatory cells to the wound bed
in PPARα-/-mice [39].
Interestingly, while keratinocyte differentia-
tion occurs during both normal epidermis renewal
and wound repair, PPARβ up-regulation is ob-
served only in the latter. We have demonstrated
that the up-regulation of the PPARβ gene is closely
associated with necrosis and the inflammatory re-
sponse it triggers. Pro-inflammatory cytokines,
e.g. TNF-α, can both increase PPARβ expression
via the stress kinases signaling pathway and trigger
the production of ligands for this receptor (fig. 2).
Consistent with an important role of PPARβ in
mediating inflammation-induced keratinocyte dif-
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ferentiation, keratinocytes derived from PPARβ-/-
mice are both severely delayed in inflammatory cy-
tokine-stimulated differentiation. Importantly, the
injury-triggered release of pro-inflammatory cy-
tokines is not only important for haemostasis, re-
cruitment of macrophages and removal of infec-
tious agents, but these cytokines are also apoptotic
signals [51]. Interestingly, recent results indicate
that keratinocytes derived from PPARβ-/-mice 
are more sensitive to TNF-α-induced apoptosis
[52]. Therefore, one of the roles of PPARβ ex-
pression after injury induced by cytokines and
bioactive lipids, would be to confer resistance
against apoptotic signals, thereby providing a crit-
ical window for the action of other factors such as
KGF, which modulate keratinocytes behavior [53].
A deficiency in PPARβ during this phase would re-
sult in an increase in the apoptosis of keratinocytes,
hence reducing the number of proliferating and
migrating cells that are vital for wound closure.
Observations made at the wound edges of
PPARβ+/-mice are indeed in agreement with this
hypothesis. Although there is higher keratinocyte
proliferation rates at the wound edges in these mu-
tant mice, the number of apoptotic cells were in-
creased dramatically [52]. Accordingly, the most
significant differences in the rate of wound closure
between wild type and PPARβ+/-mice are ob-
served during the first week of wound repair [39].
As wound repair enters into the re-epithelisation
phase, migrating keratinocytes have an important
role in rapid wound closure. The accelerated ker-
atinocyte differentiation sustained by elevated and
prolonged activation of PPARβ, as seen in ker-
atinocyte cultures, is likely to be important during
the re-epithelialisation phase, during which
PPARβ might have a specific spatio-temporal role.
For example, we have observed that PPARβ+/-
keratinocytes in culture are defective in substrate
adhesion [39]. At present, it is unclear which are
the PPARβ target genes that contribute to this
phenotype. It is worth noting, with respect to the
role of PPARβ, that the expression of PPARα in
response to inflammatory signals is very similar in
wild-type and PPARβ-/-keratinocytes, indicating
that PPARα does not compensate for the lack of
PPARβ. It also indicates that PPARα expression is
not controlled by PPARβ.
In conclusion, PPARα and PPARβ expression
and activation might participate in the sequential
regulatory events taking place during wound heal-
ing or inflammatory challenges [54]. As deviation
from this pattern may result in skin disorders, e.g.
psoriasis [55], the exploration of the role of PPARα
and PPARβ in skin disorders might open impor-
tant therapeutic perspectives and lead to the dis-
covery of additional so far unknown functions of
these PPAR isotypes.
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Conclusions
The study of the PPAR expression profiles, the
identification of target genes and ligands, and the
utilization of PPAR mutant mouse models have
unveiled distinct and often complementary physi-
ological functions of the PPARs (fig. 3). Since the
first description of the mouse PPARα as the medi-
ator of peroxisome proliferation in the liver and as
illustrated herein, PPARs have shown their im-
portance in several vertebrate physiological path-
ways, such as the maintenance of energy ho-
moeostasis and the control of the inflammatory re-
sponse. The evidence that PPARs are also impli-
wound injury
(necrosis)
inflammation
(INFγ, TNFα, others)
Stimulation of PPARβ gene
Ligand production
Activation of PPARβ LBD
resistance to apoptosis;
keratinocyte proliferation, adhesion/migration
PPARβ-dependent differentiation;
normal epidermis
renewal
FAN
N-Smase
ceramide
JNK/SAPK
AP-1
no inflammation
normal,
PPARβ-independent
differentiation
Inflammatory cells
Keratinocytes
Figure 2
Role of PPARβ during wound healing. Upon in-
jury cell necrosis triggers the production of in-
flammatory cytokines by immune cells. PPARβ
is an important transcription factor relaying
these signals (TNFα, IFNγ) at the cell surface
into specific gene expression patterns that par-
ticipate into the appropriate cellular responses
to sudden stress situations. TNF-α or IFN-γ acti-
vate the stress-associated signaling pathway
leading to the stimulation of PPARβ gene ex-
pression via an AP-1 site located in its pro-
moter. These signals also trigger the produc-
tion of PPARβ ligands that activate the receptor.
The resulting increase in PPARβ transcriptional
activity accelerates the differentiation of ker-
atinocytes and increases their resistance to
apoptotic signals. Increased proliferation and
death of keratinocytes at the edges of epider-
mal wounds in PPARβ mutant mice most likely
participate in the healing delay observed in
these animals [39, 52].
cated in cell fate is growing rapidly, and it is be-
coming clear that PPARs participate in the control
of cell proliferation and differentiation. However,
the molecular mechanisms by which PPARs coor-
dinate the regulation of these processes remain
largely unknown, and unveiling this aspect of
PPAR biology is of high interest. In addition, like
for many other nuclear receptors, the involvement
of PPARs in tissue differentiation in vivo might still
be underestimated, because of functional redun-
dancies or lethality in the null mouse lines. In these
cases the analysis of mouse lines in which specific
tissues are deficient for a given PPAR isotype will
most likely reveal additional unexpected functions
for these nuclear receptors.
I am very grateful to my colleagues B. Desvergne, L.
Michalik, N. S. Tan and S. Kersten who have been major
contributors to the work which is presented here as a syn-
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publications [22, 39, 52]. 
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